While these parameters can still be within normal range for many patients with subclinical cardiac involvement, the direct correlation suggests that changes in the size and mass of the heart can be reflected in circulating periostin levels, making it a promising biomarker for disease progression in SSc cardiomyopathy. This evidence concerns the gene POSTN and systemic sclerosis.